Suggested Remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating non-radiographic axial spondyloarthritis.
Status In progress
Process STA 2018
ID number 1419

Provisional Schedule

Committee meeting: 1 09 June 2020
Invitation to participate 09 October 2020

Project Team

Project lead Thomas Fiest

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Key events during the development of the guidance:

Date Update
09 October 2019 In progress, in progress
31 January 2019 - 28 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance